Cipla - Steady Q2; Strong Respiratory Pipeline: ICICI Securities

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..ICICI Securities Report.Cipla Ltd.’s Q2 FY22 result was above our estimates led by strong performance in India. However, we expect India growth to taper down in coming quarters with declining contribution from Covid-19 portfolio and higher base. Ebitda margin declined 120 basis points YoY to 22.2%, however in line with our estimates. We expect Ebitda margin to stabilise at 22-23% versus earlier levels of 17-19%. Consolidated revenues grew 9.6% to Rs 55.2 billion and adjusted profit after tax grew 6.9% to Rs 7.1 billion. Cipla has shown strong performance over past five to six quarters in India business led by Covid-19 portfolio as well as benefits of one India strategy undertaken in FY20 which would help in sustaining above industry growth. U.S. business would gradually scale-up on back of complex launches..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Cipla - Steady Q2; Strong Respiratory Pipeline: ICICI Securities

Cipla - Steady Q2; Strong Respiratory Pipeline: ICICI Securities

Choose a plan